George Clinical and the China Anti-Cancer Association Australia launch inaugural research seminar

26 SEPTEMBER, 2018 – (SYDNEY) In recognition of the largest non-English speaking ethnic groups in Australia, George Clinical, a leading Asia Pacific CRO, and the China Anti-Cancer Association Australia (CACA) have joined together to launch the inaugural CACA research seminar entitled: Cancer incidence, palliative care among Chinese migrants to Australia. The event, which will be […]

Read More

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO.

9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]

Read More

George Clinical leads China Component and Recruitment in World-First Large CPAP Device Trial

The Study Although Obstructive sleep apnea (OSA) is a very common condition that is associated with an increased risk of cardiovascular disease (CVD), there is much uncertainty over the effectiveness of treatment with nasal continuous positive airway pressure (CPAP) for the prevention of CVD. The SAVE trial was a multi-centre, open label, parallel, prospective, randomised, […]

Read More

China’s dynamism requires a nimble CRO with extensive research networks

China’s meteoric growth over the past twenty years (or so) has seen it go from strength to strength, particularly in the clinical trials sector. As the clinical trial market of the world’s most populous nation (and second largest economy) continues to mature, so does their regulatory requirements. These regulatory adjustments pose a risk to sponsors […]

Read More

Twitter Facebook LinkedIn